	US 12,213,990 B2
	A3 adenosine receptor ligand for use for achieving a fat loss effect
Motti Farbstein, Petach Tikva (IL); Inbal Itzhak, Kfar Saba (IL); Shira Cohen, Hod Hasharon (IL); and Pnina Fishman, Herzliya (IL)
Assigned to CAN-FITE BIOPHARMA LTD., Petach Tikva (IL)
Appl. No. 17/309,952
Filed by CAN-FITE BIOPHARMA LTD., Petach Tikva (IL)
PCT Filed Jan. 5, 2020, PCT No. PCT/IL2020/050011 § 371(c)(1), (2) Date Jul. 2, 2021, PCT Pub. No. WO2020/141535, PCT Pub. Date Jul. 9, 2020.
Claims priority of application No. 264112 (IL), filed on Jan. 6, 2019.
Prior Publication US 2022/0079968 A1, Mar. 17, 2022
Int. Cl. A61K 31/7076 (2006.01); A61K 31/4745 (2006.01); A61P 3/04 (2006.01)

CPC A61K 31/7076 (2013.01) [A61K 31/4745 (2013.01); A61P 3/04 (2018.01)]

5 Claims

1. A method for treating a subject comprising administering to said subject an amount of an A₃adenosine receptor (A₃AR) ligand, the amount being effective to achieve at least one fat loss effect selected from:

reduce weight of the subject;

reduce body fat mass in the subject

wherein said fat loss effect refers to reducing adipose tissues that are intended to store fat and excluding ectopic fat,

wherein said A₃AR ligand inhibits adipocyte proliferation, and

wherein said A₃AR ligand is CI-IB-MECA or N-(3,4-Dichloro-phenyl)-2-cyclohexyl-1H-imidazo [4,5-c]quinolin-4-amine (CF602).